Suppr超能文献

中危子宫内膜癌患者辅助高剂量率阴道近距离放疗后的急性和晚期阴道毒性:透明质酸局部治疗是否具有临床益处?

Acute and late vaginal toxicity after adjuvant high-dose-rate vaginal brachytherapy in patients with intermediate risk endometrial cancer: is local therapy with hyaluronic acid of clinical benefit?

作者信息

Laliscia Concetta, Delishaj Durim, Fabrini Maria Grazia, Gonnelli Alessandra, Morganti Riccardo, Perrone Franco, Tana Roberta, Paiar Fabiola, Gadducci Angiolo

机构信息

Department of Translational Medicine, Division of Radiation Oncology.

Department of Experimental and Clinical Medicine, Section of Statistics.

出版信息

J Contemp Brachytherapy. 2016 Dec;8(6):512-517. doi: 10.5114/jcb.2016.64511. Epub 2016 Dec 9.

Abstract

PURPOSE

The aim of the present study was to evaluate the effectiveness of hyaluronic acid (HA) in the prevention of acute and late vaginal toxicities after high-dose-rate (HDR) vaginal brachytherapy (BT).

MATERIAL AND METHODS

Between January 2011 and January 2015, we retrospectively analyzed 126 patients with endometrial cancer who underwent extrafascial hysterectomy with or without lymphadenectomy and adjuvant HDR-vaginal BT +/- adjuvant chemotherapy. The total dose prescription was 21 Gy in 3 fractions (one fraction for week). Vaginal ovules containing 5 mg of HA were given for whole duration of vaginal BT and for the two following weeks. Acute and late toxicities were evaluated according to CTCAE vs 4.02.

RESULTS

According to the revised FIGO 2009 classification, most tumors were in stage IA (30.9%) and in stage IB (57.9%). Thirty-three patients (26.2%) received adjuvant chemotherapy before vaginal BT. Five-year disease-free survival (DFS) and five-year overall survival (OS) were 88% and 93%, respectively. The most common grade 1-2 acute toxicities were vaginal inflammation (18 patients, 14.3%) and dyspareunia (7 patients, 5.5%). Two patients (1.6%) had more than one toxicity. Late toxicity occurred in 20 patients (15.9%). Grade 1-2 late toxicities were fibrosis (14 patients, 11.1%) and telangiectasias (7 patients, 5.5%). Six patients (4.8%) had more than one late toxicity. No grade 3 or higher acute or late toxicities were observed.

CONCLUSIONS

These results appear to suggest that the local therapy with HA is of clinical benefit for intermediate risk endometrial cancer patients who receive adjuvant HDR-vaginal BT after surgery. A randomized trial comparing HA treatment vs. no local treatment in this clinical setting is warranted to further evaluate the efficacy of HA in preventing vaginal BT-related vaginal toxicity.

摘要

目的

本研究旨在评估透明质酸(HA)在预防高剂量率(HDR)阴道近距离放射治疗(BT)后急性和晚期阴道毒性方面的有效性。

材料与方法

2011年1月至2015年1月期间,我们回顾性分析了126例子宫内膜癌患者,这些患者接受了筋膜外子宫切除术,伴或不伴淋巴结清扫术以及辅助性HDR阴道BT和/或辅助化疗。总剂量处方为21 Gy,分3次给予(每周1次)。在整个阴道BT期间以及随后的两周内给予含5 mg HA的阴道栓剂。根据CTCAE v4.02评估急性和晚期毒性。

结果

根据修订后的2009年FIGO分类,大多数肿瘤处于IA期(30.9%)和IB期(57.9%)。33例患者(26.2%)在阴道BT前接受了辅助化疗。五年无病生存率(DFS)和五年总生存率(OS)分别为88%和93%。最常见的1 - 2级急性毒性是阴道炎症(18例患者,14.3%)和性交困难(7例患者,5.5%)。2例患者(1.6%)出现不止一种毒性。20例患者(15.9%)发生晚期毒性。1 - 2级晚期毒性为纤维化(14例患者,11.1%)和毛细血管扩张(7例患者,5.5%)。6例患者(4.8%)出现不止一种晚期毒性。未观察到3级或更高等级的急性或晚期毒性。

结论

这些结果似乎表明,对于术后接受辅助性HDR阴道BT的中危子宫内膜癌患者,HA局部治疗具有临床益处。有必要在这种临床环境中进行一项比较HA治疗与不进行局部治疗的随机试验,以进一步评估HA预防阴道BT相关阴道毒性的疗效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de21/5241378/ad301c00caeb/JCB-8-28876-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验